EnterpriseSG Opens Boston Kendall Square Bio Hub and Signs Economic Agreement with Massachusetts
Securing Kendall Square Foothold and Signing Economic Agreement with Massachusetts
Enterprise Singapore (EnterpriseSG), under the Singapore Ministry of Trade and Industry, held an inauguration ceremony for its new Overseas Centre at the Raffles Hotel in Boston and signed its first-ever state-level economic agreement with the Massachusetts Office of International Trade and Investment (MOITI). This Boston Centre is Singapore's fifth US base, established in Kendall Square, Cambridge, the heart of the global biotech ecosystem. As bilateral trade has more than doubled since 2021 to reach USD 2.75 billion in 2025, this initiative aims to institutionally support technological partnerships in advanced industries such as Life Sciences and Artificial Intelligence (AI).
Overcoming the Crisis of Lacking Domestic Unicorns and Fostering Bio Clusters
Since 2000, the Singapore government has nurtured biomedical science as one of its four economic pillars, but it has yet to produce a global blockbuster drug. The crisis in the sector has intensified following the closure of cell therapy company Tessa Therapeutics, which had previously raised over USD 200 million due to poor clinical trial results, and BioNTech's (BNTX) decision to halt operations at its Singapore mRNA plant by 2027. Consequently, EnterpriseSG has adopted a strategy to move beyond domestic-centric research and accelerate commercialization by expanding into Boston, the world's largest innovation hub.
Connecting with Local VCs and Utilizing Bi-directional Clinical and Production Infrastructure
The Boston Centre serves as a window to resolve development bottlenecks by directly connecting Singaporean biotechs with local venture capitalists (VCs) and researchers. For instance, Cirrus Therapeutics, a preclinical biotech developing a gene therapy for age-related macular degeneration (AMD), is combining Boston-based talent with the clinical networks of major Singaporean hospitals. Mutual production cooperation is also strengthening, as demonstrated by Vertex Holdings, an affiliate of Singapore's sovereign wealth fund, investing USD 100M in nine local startups, including the CDMO company ElevateBio.
A Bridgehead for Entering the Asian Market and Accelerating Global Scale-up
For Boston investors, Singapore is regarded as a key bridgehead for tech scouting promising pipelines in Southeast Asia and conducting Asian clinical trials. Notably, Nanyang Biologics, a Singaporean AI drug discovery platform, is moving toward a public listing through a USD 1.5B merger with the Nasdaq SPAC RF Acquisition Corp II (RFAI). Ultimately, the opening of this Boston hub signifies the completion of a strategic pathway that directly links Asian biotechs to global clinical entry and listings on US capital markets.
EnterpriseSG's expansion into Kendall Square is a national-level strategy to overcome domestic biotech limitations—such as the bankruptcy of Tessa Therapeutics and BioNTech's plant withdrawal—leveraging bilateral trade that has grown to USD 2.75 billion as of 2025. From an investor perspective, cross-border exit opportunities are expanding, as evidenced by Vertex Holdings' $100 million funding of Massachusetts startups like ElevateBio and Nanyang Biologics' $1.5 billion Nasdaq SPAC listing. From a researcher's perspective, this serves as an opportunity for preclinical gene therapies targeting the $10 billion age-related macular degeneration (AMD) market, such as those from Cirrus Therapeutics, to leverage the integration of Boston-based R&D with Asian clinical infrastructure to compete against existing standard-of-care treatments like Eylea. In the mid-to-long term, this is expected to facilitate new drug discovery in Asia by top-tier Boston venture capital firms such as Polaris Partners, thereby driving a revaluation of the broader Asia-Pacific biotech sector.
Source: FierceBiotech (rss)